Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer | Zendy

Hans Prenen | Zendy; Geva | Zendy; Loredana Vecchione | Zendy; Tejpar | Zendy; Hubert Piessevaux | Zendy; Van Cutsem | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer

Author(s) -

Hans Prenen,

Geva,

Loredana Vecchione,

Tejpar,

Hubert Piessevaux,

Van Cutsem

Publication year - 2013

Publication title -

oncotargets and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.054

H-Index - 60

ISSN - 1178-6930

DOI - 10.2147/ott.s41383

Subject(s) - bevacizumab , medicine , irinotecan , oxaliplatin , folfiri , colorectal cancer , folfox , chemotherapy , cetuximab , regimen , oncology , fluorouracil , combination chemotherapy , surgery , cancer

The combination of chemotherapy and bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor, is consistently being used as first- and second-line treatment in patients with metastatic colorectal cancer (mCRC). There is little data of the activity of bevacizumab in chemorefractory mCRC patients. The aim of this retrospective single center study was to evaluate the activity of bevacizumab combined with chemotherapy in this study population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research